Site Search
Displaying results 51 - 60 of 573
Resource | Publications,
The increasing trend in hepatitis-related deaths is alarming and action can be taken. Cirrhosis and liver cancer due to hepatitis is preventable as treatment prevents disease progression and hepatitis C infection is curable. The Global Health Sector Strategy (GHSS) for Viral Hepatitis 2016-2021 outlines the vision of elimination of viral hepatitis as a public threat by 2030, as part of Sustainable Development Goals for health.
Many countries are developing their national response for comprehensive prevention, treatment and care for hepatitis, as part of Health for All. Delivery of services for screening, diagnosis and treatment of hepatitis B and C as part of existing health services underlies universal health coverage. Capacity to deliver good quality services by all cadres of health care providers for hepatitis care is important.
These training modules have been developed by WHO South-East Asia and Western Pacific Regional Offices as part of biregional collaboration, and were developed following global WHO guidelines for hepatitis which can be adapted to country-specific needs. The modules are available publicly for the use capacity building of health care providers.
Resource | Publications,
HIV-1 drug resistance (HIVDR) genotyping is an essential component of the WHO global HIVDR surveillance strategy. Plasma “gold standard” specimen type for HIVDR genotyping, but its use may not be feasible in rural, remote areas in low- and middle-income countries, since preparing and storing it require personnel and laboratory infrastructure that are often lacking. An alternative specimen type is dried blood spots (DBS), which can be made without special laboratory processing. DBS are more easily transported than plasma because they can be shipped at ambient temperature as non-hazardous materials using regular mail or courier services.
Resource | Publications,
This technical guidance describes the methods and implementation considerations to monitor the prevalence of HIV drug resistance among PrEP users diagnosed with HIV through a cross-sectional survey. The outcomes of the survey will be used to inform the selection of maximally effective first-line combination antiretroviral therapy for PrEP users who acquire HIV.
Resource | Guidelines,
The WHO HIV Drug Resistance Network (HIVResNet) HIV drug resistance laboratory operational framework describes how WHO HIVResNet laboratories function to support national, regional and global HIV drug resistance surveillance by providing accurate genotyping results in a standardized format according to WHO specifications.
The aim of the operational framework is to ensure 1) accurate collection, handling, shipment and storage of specimens collected in countries implementing HIV drug resistance surveillance; and 2) the availability of quality-assured HIV genotyping laboratory services producing comparable and reliable results at the national, regional and global levels.
This publication updates the WHO HIVResNet HIV drug resistance laboratory operational framework published in 2017 and reflects technical and strategic developments over the past three years.
Resource | Publications,
Sexual health services for the YKPs are key programs that contribute to reducing the increased risks of STI and HIV infection, including not only HIV/ STIs services, but also harm reduction, mental health and specialized services for each population. It is essential to understand the characteristics of the YKPs in order to promote their access to sexual health services.
The study, with the sample of 65 people who self-identified as YKP, investigated their views on sexual health and the factors influencing their access to and use of sexual health services. The average age of the participants is 20.5 years old. The age at which they initiated sexual experiences varies widely. Most participants had their first sexual intercourse between the ages of 18 and 20, with the earliest at 14 years old.
Resource | Publications,
Rights in a Pandemic outlines 10 immediate areas for action for governments towards building effective, rights-based COVID-19 responses. These include taking proactive measures to ensure that people, particularly people in vulnerable groups, can access HIV treatment and prevention services, designating and supporting essential workers, including community-led organizations, and implementing measures to prevent and address gender-based violence. The report builds on Rights in the time of COVID-19, released by UNAIDS in March 2020, which urged countries to take a human rights approach in responding to COVID-19, in line with best practices from 40 years of responding to HIV.
Resource | Publications,
WFP has led the development and finalization of a key document for integrating HIV within the Cluster Response, along with UNHCR and UNAIDS support. The guidance key consideration that affect the HIV response in humanitarian settings, as well as provides key actions that are required for a minimum initial response. Covering health, protection, nutrition, and food security, the guidance document is a comprehensive tool for those working in humanitarian response and fragile contexts.
Resource | Publications,
Areas of Africa endemic for Buruli ulcer (BU), caused by Mycobacterium ulcerans, also have a high prevalence of human immunodeficiency virus (HIV), with adult prevalence rates between 1% and 5%. However, there is limited information on the prevalence of BU–HIV coinfection. Preliminary evidence suggests that HIV infection may increase the risk of BU disease. In the Médecins Sans Frontières project in Akonolinga, Cameroon, HIV prevalence was approximately 3–6 times higher among BU patients than the regional estimated HIV prevalence. Similarly in Benin and Ghana, BU patients were 8 times and 3 times respectively more likely to have HIV infection than those without BU. Further study is needed to clarify this association and enhance knowledge about the prevalence of BU–HIV coinfection in endemic areas.
Resource | Publications,
In April 2020, new directions in global guidance for HIV strategic information and treatment monitoring were updated. This technical update outlines the key developments with respect to recommended indicators and approaches and tools for monitoring antiretroviral drug toxicity with the purpose of strengthening country implementation and ensuring the safe use of antiretroviral drugs.
Resource | Publications,
This policy brief highlights key elements of the 2020 WHO consolidated HIV strategic information guidelines pertinent to HIV testing and treatment for children. It is designed to support country strategic information teams to choose, collect and systematically analyse the strategic information needed to strengthen programme management and monitoring of testing and treatment for children and adolescents.